Rheumatology:超氧化物歧化酶在与间质性肺病相关的抗MDA5阳性皮肌炎中的价值评估

2022-07-28 紫菀款冬 MedSci原创

探讨抗黑色素瘤分化相关基因5抗体阳性皮肌炎(抗MDA5阳性DM)患者血清超氧化物歧化酶(SOD)与间质性肺病(ILD)的关系。

目的:探讨抗黑色素瘤分化相关基因5抗体阳性皮肌炎(抗MDA5阳性DM)患者血清超氧化物歧化酶(SOD)间质性肺病(ILD)的关系。

方法:在该回顾性研究中,对某医院90例健康体检者血清SOD进行检测。94名抗MDA5阳性DM住院患者患有ILD。测定这些患者血清SOD、血清铁蛋白和自身抗体水平,并进行肺部高分辨率计算机断层扫描。

结果:抗MDA5阳性DM组血清SOD水平明显低于对照组。治疗前,抗MDA5抗体和抗Ro-52抗体均阳性的患者的SOD水平显著低于仅抗MDA5抗体阳性的患者。

治疗前,高血清铁蛋白组的SOD水平显著低于低血清铁蛋白组。治疗后,ILD加重患者的血清SOD水平降低,而ILD缓解患者的血清SOD水平升高。治疗前,死亡组的SOD水平显著低于存活组。

结论:在抗MDA5阳性糖尿病患者中

(1)治疗前SOD水平较低表明疾病中存在氧化应激

(2)血清SOD水平受抗Ro-52抗体和铁蛋白的影响

(3)抗MDA5阳性DM患者血清SOD水平与ILD密切相关,提示SOD可作为评价这些患者ILD变化的有效指标

(4)超氧化物歧化酶水平低是这些患者预后不良的重要指标,值得风湿病学家关注。

文献来源:

Huang W, Chen D, Wang Z, et al. Evaluating the value of superoxide dismutase in anti-MDA5-positive dermatomyositis associated with interstitial lung disease [published online ahead of print, 2022 Jul 22]. Rheumatology (Oxford). 2022;keac429. doi:10.1093/rheumatology/keac429

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943564, encodeId=e5e2194356425, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Jul 02 13:49:59 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813525, encodeId=996718135254a, content=<a href='/topic/show?id=4db7928e045' target=_blank style='color:#2F92EE;'>#超氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92870, encryptionId=4db7928e045, topicName=超氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 28 08:49:59 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062595, encodeId=08f020625959d, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 03 09:49:59 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671997, encodeId=76f816e199754, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sat Nov 05 22:49:59 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815875, encodeId=6be318158e5c4, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Apr 04 01:49:59 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309291, encodeId=cb021309291e8, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jul 26 04:49:59 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
    2023-07-02 wetgdt
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943564, encodeId=e5e2194356425, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Jul 02 13:49:59 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813525, encodeId=996718135254a, content=<a href='/topic/show?id=4db7928e045' target=_blank style='color:#2F92EE;'>#超氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92870, encryptionId=4db7928e045, topicName=超氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 28 08:49:59 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062595, encodeId=08f020625959d, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 03 09:49:59 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671997, encodeId=76f816e199754, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sat Nov 05 22:49:59 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815875, encodeId=6be318158e5c4, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Apr 04 01:49:59 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309291, encodeId=cb021309291e8, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jul 26 04:49:59 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943564, encodeId=e5e2194356425, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Jul 02 13:49:59 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813525, encodeId=996718135254a, content=<a href='/topic/show?id=4db7928e045' target=_blank style='color:#2F92EE;'>#超氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92870, encryptionId=4db7928e045, topicName=超氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 28 08:49:59 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062595, encodeId=08f020625959d, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 03 09:49:59 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671997, encodeId=76f816e199754, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sat Nov 05 22:49:59 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815875, encodeId=6be318158e5c4, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Apr 04 01:49:59 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309291, encodeId=cb021309291e8, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jul 26 04:49:59 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943564, encodeId=e5e2194356425, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Jul 02 13:49:59 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813525, encodeId=996718135254a, content=<a href='/topic/show?id=4db7928e045' target=_blank style='color:#2F92EE;'>#超氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92870, encryptionId=4db7928e045, topicName=超氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 28 08:49:59 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062595, encodeId=08f020625959d, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 03 09:49:59 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671997, encodeId=76f816e199754, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sat Nov 05 22:49:59 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815875, encodeId=6be318158e5c4, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Apr 04 01:49:59 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309291, encodeId=cb021309291e8, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jul 26 04:49:59 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
    2022-11-05 amy0559
  5. [GetPortalCommentsPageByObjectIdResponse(id=1943564, encodeId=e5e2194356425, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Jul 02 13:49:59 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813525, encodeId=996718135254a, content=<a href='/topic/show?id=4db7928e045' target=_blank style='color:#2F92EE;'>#超氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92870, encryptionId=4db7928e045, topicName=超氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 28 08:49:59 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062595, encodeId=08f020625959d, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 03 09:49:59 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671997, encodeId=76f816e199754, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sat Nov 05 22:49:59 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815875, encodeId=6be318158e5c4, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Apr 04 01:49:59 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309291, encodeId=cb021309291e8, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jul 26 04:49:59 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1943564, encodeId=e5e2194356425, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Jul 02 13:49:59 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813525, encodeId=996718135254a, content=<a href='/topic/show?id=4db7928e045' target=_blank style='color:#2F92EE;'>#超氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92870, encryptionId=4db7928e045, topicName=超氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Dec 28 08:49:59 CST 2022, time=2022-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062595, encodeId=08f020625959d, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Thu Nov 03 09:49:59 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671997, encodeId=76f816e199754, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sat Nov 05 22:49:59 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815875, encodeId=6be318158e5c4, content=<a href='/topic/show?id=82e99e291b0' target=_blank style='color:#2F92EE;'>#间质性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97291, encryptionId=82e99e291b0, topicName=间质性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Tue Apr 04 01:49:59 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309291, encodeId=cb021309291e8, content=<a href='/topic/show?id=e947e198270' target=_blank style='color:#2F92EE;'>#皮肌炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71982, encryptionId=e947e198270, topicName=皮肌炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Jul 26 04:49:59 CST 2022, time=2022-07-26, status=1, ipAttribution=)]

相关资讯

European Radiology:从影像学角度,明确特发性炎症性肌病与特异性自身抗体之间的关系

特发性炎症性肌病(IIMs)是一组罕见的、异质性的多系统自身免疫性疾病,以骨骼肌、皮肤和其他器官受累为主要特征。间质性肺病(ILD)是最常见的肌肉外IIM受累表现之一。

ARD:肺分子特征的综合分析揭示了系统性硬化症相关间质性肺病的关键驱动因素

肺组织的综合转录组分析揭示了 SSc-ILD 中纤维化的关键特征。基于网络的贝叶斯方法提供了对适用于治疗 SSc-ILD 的关键调控基因和分子靶点的深入见解。

第二届长三角间质性肺病论坛暨第四届呼吸疾病诊治论坛

第二届长三角间质性肺病论坛暨第四届呼吸疾病诊治论坛

Eur Respir J:细颗粒物成分与类风湿性关节炎患者间质性肺病的关系

暴露于PM2.5的组分,尤其是铵,会增加类风湿性关节炎患者的ILD风险。

间质性肺病的肺动脉高压研究进展

肺循环领域的疾病治疗方法已经取得了一些进展,但 PH-ILD 治疗的持续创新直到最近才出现,主要集中在 IIP,主要集中在 IPF。

European Radiology:对于偶然发现的肺部间质性改变,究竟有何临床意义?

现阶段,人们已经认识到肺间质异常(ILAs)与不良的临床预后和死亡率的增加有关,影像学进展率从2年的20%到5年的63%不等。